Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2022 Apr 5

PMID 35378697

Authors

Pavlos Chryssafidis

Athanasios A Tsekouras

Panos Macheras

Affiliations

Soon will be listed here.

Abstract

Purpose: To develop physiologically based finite time pharmacokinetic (PBFTPK) models for the analysis of oral pharmacokinetic data.

Methods: The models are based on the passive drug diffusion mechanism under the sink conditions principle. Up to three drug successive input functions of constant rate operating for a total time τ are considered. Differential equations were written for all these models assuming linear one- or two-compartment-model disposition. The differential equations were solved and functions describing the concentration of drug as a function of time for the central and the peripheral compartment were derived. The equations were used to generate simulated data and they were also fitted to a variety of experimental literature oral pharmacokinetic data.

Results: The simulated curves resemble real life data. The end of the absorption processes τ is either equal to t or longer than t at the descending portion of the concentration time curve. Literature oral pharmacokinetic data of paracetamol, ibuprofen, almotriptan, cyclosporine (a total of four sets of data), and niraparib were analyzed using the PBFTPK models. Estimates for τ corresponding to a single or two or three different in magnitude input rates were derived along with the other model parameters for all data analyzed.

Conclusions: The PBFTPK models are a powerful tool for the analysis of oral pharmacokinetic data since they rely on the physiologically sound concept of finite absorption time.

Citing Articles

FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes.

Toulitsis E, Tsekouras A, Macheras P Pharmaceutics. 2024; 16(11).

PMID: 39598557 PMC: 11597828. DOI: 10.3390/pharmaceutics16111435.

Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling.

Arteaga-Bejarano J, Torres S J Pharmacokinet Pharmacodyn. 2024; 51(6):825-839.

PMID: 39060788 PMC: 11579191. DOI: 10.1007/s10928-024-09920-z.

Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence.

Tsekouras A, Macheras P Pharm Res. 2024; 41(7):1413-1425.

PMID: 38898304 DOI: 10.1007/s11095-024-03727-w.

Importance of Considering Fed-State Gastrointestinal Physiology in Predicting the Reabsorption of Enterohepatic Circulation of Drugs.

Nakamura K, Kambayashi A, Onoue S Pharm Res. 2024; 41(4):673-685.

PMID: 38472609 PMC: 11636765. DOI: 10.1007/s11095-024-03669-3.

Coupling Drug Dissolution with BCS.

Simitopoulos A, Tsekouras A, Macheras P Pharm Res. 2024; 41(3):481-491.

PMID: 38291164 PMC: 11636680. DOI: 10.1007/s11095-024-03661-x.

References

Lovering E, McGilveray I, McMillan I, Tostowaryk W . Comparative bioavailabilities from truncated blood level curves. J Pharm Sci. 1975; 64(9):1521-4. DOI: 10.1002/jps.2600640921. View

Sugano K . Lost in modelling and simulation?. ADMET DMPK. 2022; 9(2):75-109. PMC: 8920108. DOI: 10.5599/admet.923. View

Chryssafidis P, Tsekouras A, Macheras P . Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. Pharm Res. 2021; 38(8):1345-1356. DOI: 10.1007/s11095-021-03078-w. View

Iranpour P, Lall C, Houshyar R, Helmy M, Yang A, Choi J . Altered Doppler flow patterns in cirrhosis patients: an overview. Ultrasonography. 2015; 35(1):3-12. PMC: 4701371. DOI: 10.14366/usg.15020. View

Macheras P, Chryssafidis P . Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts. Pharm Res. 2020; 37(10):187. DOI: 10.1007/s11095-020-02894-w. View

Abuhelwa A, Foster D, Upton R . A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time. AAPS J. 2016; 18(5):1322-1333. DOI: 10.1208/s12248-016-9953-7. View

Sjogren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernas H . In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013; 49(4):679-98. DOI: 10.1016/j.ejps.2013.05.019. View

Sager J, Yu J, Ragueneau-Majlessi I, Isoherranen N . Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos. 2015; 43(11):1823-37. PMC: 4613950. DOI: 10.1124/dmd.115.065920. View

Atkinson H, Stanescu I, Frampton C, Salem I, Beasley C, Robson R . Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. Clin Drug Investig. 2015; 35(10):625-32. PMC: 4579261. DOI: 10.1007/s40261-015-0320-8. View

10.

Ismailos G, Reppas C, Dressman J, Macheras P . Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol. 1991; 43(4):287-9. DOI: 10.1111/j.2042-7158.1991.tb06688.x. View

11.

Mueller E, Kovarik J, van Bree J, Grevel J, Lucker P, Kutz K . Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res. 1994; 11(1):151-5. DOI: 10.1023/a:1018922517162. View

12.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M . Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol. 2017; 81(1):39-46. PMC: 5754411. DOI: 10.1007/s00280-017-3455-x. View

13.

Macheras P . On an Unphysical Hypothesis of Bateman Equation and its Implications for Pharmacokinetics. Pharm Res. 2019; 36(7):94. DOI: 10.1007/s11095-019-2633-4. View

14.

Brown J, Chien C, Timmins P, Dennis A, Doll W, Sandefer E . Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci. 2013; 102(6):1742-1751. DOI: 10.1002/jps.23476. View

15.

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

16.

Wu C, Benet L . Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005; 22(1):11-23. DOI: 10.1007/s11095-004-9004-4. View

17.

Macheras P, Karalis V . A non-binary biopharmaceutical classification of drugs: the ABΓ system. Int J Pharm. 2014; 464(1-2):85-90. DOI: 10.1016/j.ijpharm.2014.01.022. View

18.

Rinaki E, Valsami G, Macheras P . Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res. 2004; 20(12):1917-25. DOI: 10.1023/b:pham.0000008037.57884.11. View

19.

Charkoftaki G, Dokoumetzidis A, Valsami G, Macheras P . Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS. Pharm Res. 2012; 29(11):3188-98. DOI: 10.1007/s11095-012-0815-4. View

20.

Macheras P, Iliadis A, Melagraki G . A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs. Eur J Pharm Sci. 2018; 117:98-106. DOI: 10.1016/j.ejps.2018.02.003. View